Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRTX NASDAQ:LRMR NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTXGalera Therapeutics$0.09-3.7%$0.10$0.02▼$0.15$14.13M2.6187,218 shs1,197 shsLRMRLarimar Therapeutics$3.29+0.9%$3.64$2.71▼$6.42$341.78M0.833.11 million shs1.75 million shsORMPOramed Pharmaceuticals$4.57-0.7%$4.11$1.98▼$5.19$187.05M1.21241,770 shs281,072 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTXGalera Therapeutics0.00%+3.86%-3.68%+122.63%+211.22%LRMRLarimar Therapeutics0.00%-10.93%+2.84%-35.45%+3.82%ORMPOramed Pharmaceuticals0.00%-1.50%+23.99%+33.72%+110.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTXGalera Therapeutics$0.09-3.7%$0.10$0.02▼$0.15$14.13M2.6187,218 shs1,197 shsLRMRLarimar Therapeutics$3.29+0.9%$3.64$2.71▼$6.42$341.78M0.833.11 million shs1.75 million shsORMPOramed Pharmaceuticals$4.57-0.7%$4.11$1.98▼$5.19$187.05M1.21241,770 shs281,072 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTXGalera Therapeutics0.00%+3.86%-3.68%+122.63%+211.22%LRMRLarimar Therapeutics0.00%-10.93%+2.84%-35.45%+3.82%ORMPOramed Pharmaceuticals0.00%-1.50%+23.99%+33.72%+110.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTXGalera Therapeutics 0.00N/AN/AN/ALRMRLarimar Therapeutics 3.09Buy$12.71286.45% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, GRTX, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026LRMRLarimar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/30/2026LRMRLarimar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026LRMRLarimar Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.006/11/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/18/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $12.004/21/2026LRMRLarimar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/AORMPOramed Pharmaceuticals$2M93.53$0.09 per share50.70$5.02 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTXGalera Therapeutics-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%8/12/2026 (Estimated)LRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)ORMPOramed Pharmaceuticals$64.05M$2.591.76N/AN/AN/A-5.37%-4.83%8/13/2026 (Estimated)Latest ORMP, GRTX, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRTXGalera TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.255.47%N/A9.65%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTXGalera TherapeuticsN/A9.749.74LRMRLarimar TherapeuticsN/A4.294.29ORMPOramed PharmaceuticalsN/A6.456.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTXGalera Therapeutics50.77%LRMRLarimar Therapeutics91.92%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipGRTXGalera Therapeutics12.90%LRMRLarimar Therapeutics4.50%ORMPOramed Pharmaceuticals17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRTXGalera Therapeutics30160.43 million47.38 millionOptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionableORMPOramed Pharmaceuticals1040.93 million33.64 millionOptionableORMP, GRTX, and LRMR HeadlinesRecent News About These CompaniesOramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in StockJuly 5 at 5:17 AM | americanbankingnews.comInsider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells $611,020.00 in StockJuly 5 at 4:37 AM | americanbankingnews.comInsider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in StockJuly 3 at 6:21 AM | insidertrades.comOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25, 2026 | prnewswire.comORMP: View inclusion in Russell indexes as positive that could raise awareness in investment communityJune 18, 2026 | msn.comOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesJune 17, 2026 | prnewswire.comORMP: Strategically acquiring interests in medtech & technology companiesJune 8, 2026 | msn.comOramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment DirectionMay 22, 2026 | seekingalpha.comOramed Pharmaceuticals Inc.May 18, 2026 | marketwatch.comOramed Pharmaceuticals Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMPMay 15, 2026 | benzinga.comOramed Pharmaceuticals IncorporatedApril 15, 2026 | edition.cnn.comOramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38March 27, 2026 | msn.comOramed: Q4 Earnings SnapshotMarch 26, 2026 | stamfordadvocate.comSLifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with OramedMarch 26, 2026 | finanznachrichten.deLifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to ProfitabilityMarch 13, 2026 | quiverquant.comQLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyMarch 13, 2026 | globenewswire.comOramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | finanznachrichten.deOramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | prnewswire.comLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyJanuary 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, GRTX, and LRMR Company DescriptionsGalera Therapeutics NASDAQ:GRTX$0.09 0.00 (-3.72%) As of 09:53 AM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Larimar Therapeutics NASDAQ:LRMR$3.29 +0.03 (+0.92%) Closing price 04:00 PM EasternExtended Trading$3.34 +0.04 (+1.37%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Oramed Pharmaceuticals NASDAQ:ORMP$4.57 -0.03 (-0.65%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.00 (+0.11%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
